F8 and hemophilia: In the last 13 years, adeno-associated virus (AAV)-based gene therapy for haemophilia, which involves the transfer of genes for FVIII or FIX to target cells following a single infusion, has advanced substantially [2, 4]; the aim of which is to enable long-term endogenous coagulation factor production [4].